Increased expression of CD81 is associated with poor prognosis of prostate cancer and increases the progression of prostate cancer cells in vitro

Zhang,Yu; Qian,Haining; Xu,An; Yang,Ganggang

doi:10.3892/etm.2019.8244

Increased expression of CD81 is associated with poor prognosis of prostate cancer and increases the progression of prostate cancer cells in vitro

Authors:
- Yu Zhang
- Haining Qian
- An Xu
- Ganggang Yang
View Affiliations

Affiliations: Department of Urology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200336, P.R. China
Published online on: November 26, 2019 https://doi.org/10.3892/etm.2019.8244
Pages: 755-761

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

CD81, a member of the tetraspanin family, has been revealed to be upregulated and associated with prognosis in several types of cancer; however, this relationship has not been explored in prostate cancer. The present study aimed to investigate the prognostic significance and functional role of CD81 in prostate cancer. The expression of CD81 in prostate cancer tissues and cell lines was evaluated using qRT‑PCR analysis. Kaplan‑Meier survival analysis and Cox regression analysis were conducted to explore the prognostic significance of CD81. Cell experiments were used to explore the effects of CD81 on cell proliferation, migration, and invasion in prostate cell lines in vitro. The expression of CD81 was increased in both prostate cancer tissues and cell lines. Upregulation of CD81 was significantly associated with lymph node metastasis and TNM stage. Moreover, patients with high CD81 levels had poorer overall survival than those with lower levels. Additionally, tumor cell proliferation, migration, and invasion were inhibited by knockdown of CD81. The present results indicated that CD81 plays an oncogenic role in prostate cancer. Overexpression of CD81 may serve as a prognostic biomarker and therapeutic target and is involved in the progression of prostate cancer.

View Figures

View References

1	Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, Bonaventure A, Valkov M, Johnson CJ, Estève J, et al: Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): Analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 391:1023–1075. 2018. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
3	Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, Stein KD, Alteri R and Jemal A: Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 66:271–289. 2016. View Article : Google Scholar : PubMed/NCBI
4	Abu-Bakr El-Bayoumy AS, Hessien Keshta AT, Sallam KM, Ebeid NH, Elsheikh HM and Bayoumy BE: Extraction, purification of prostate-specific antigen (PSA), and establishment of radioimmunoassay system as a diagnostic tool for prostate disorders. J Immunoassay Immunochem. 39:12–29. 2018. View Article : Google Scholar : PubMed/NCBI
5	Caram ME, Skolarus TA and Cooney KA: Limitations of prostate-specific antigen testing after a prostate cancer diagnosis. Eur Urol. 70:209–210. 2016. View Article : Google Scholar : PubMed/NCBI
6	Amiya Y, Yamada Y, Sugiura M, Sasaki M, Shima T, Suzuki N, Nakatsu H, Murakami S and Shimazaki J: Treatment of locally advanced prostate cancer (Stage T3). Jpn J Clin Oncol. 47:257–261. 2017. View Article : Google Scholar : PubMed/NCBI
7	Levy S and Shoham T: The tetraspanin web modulates immune-signalling complexes. Nat Rev Immunol. 5:136–148. 2005. View Article : Google Scholar : PubMed/NCBI
8	Hemler ME: Tetraspanin functions and associated microdomains. Nat Rev Mol Cell Biol. 6:801–811. 2005. View Article : Google Scholar : PubMed/NCBI
9	Bassani S and Cingolani LA: Tetraspanins: Interactions and interplay with integrins. Int J Biochem Cell Biol. 44:703–708. 2012. View Article : Google Scholar : PubMed/NCBI
10	Oren R, Takahashi S, Doss C, Levy R and Levy S: TAPA-1, the target of an antiproliferative antibody, defines a new family of transmembrane proteins. Mol Cell Biol. 10:4007–4015. 1990. View Article : Google Scholar : PubMed/NCBI
11	Vences-Catalan F, Rajapaksa R, Srivastava MK, Marabelle A, Kuo CC, Levy R and Levy S: Tetraspanin CD81, a modulator of immune suppression in cancer and metastasis. Oncoimmunology. 5:e11203992015. View Article : Google Scholar : PubMed/NCBI
12	Vences-Catalan F, Duault C, Kuo CC, Rajapaksa R, Levy R and Levy S: CD81 as a tumor target. Biochem Soc Trans. 45:531–535. 2017. View Article : Google Scholar : PubMed/NCBI
13	Zhang N, Zuo L, Zheng H, Li G and Hu X: Increased expression of CD81 in breast cancer tissue is associated with reduced patient prognosis and increased cell migration and proliferation in MDA-MB-231 and MDA-MB-435S human breast cancer cell lines in vitro. Med Sci Monit. 24:5739–5747. 2018. View Article : Google Scholar : PubMed/NCBI
14	Bettin A, Reyes I and Reyes N: Gene expression profiling of prostate cancer-associated genes identifies fibromodulin as potential novel biomarker for prostate cancer. Int J Biol Markers. 31:e153–162. 2016. View Article : Google Scholar : PubMed/NCBI
15	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
16	Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, Fossati N, Gross T, Henry AM, Joniau S, et al: EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: Screening, diagnosis, and local treatment with curative intent. Eur Urol. 71:618–629. 2017. View Article : Google Scholar : PubMed/NCBI
17	Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, et al: EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: Treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 71:630–642. 2017. View Article : Google Scholar : PubMed/NCBI
18	Costa-Pinheiro P, Montezuma D, Henrique R and Jeronimo C: Diagnostic and prognostic epigenetic biomarkers in cancer. Epigenomics. 7:1003–1015. 2015. View Article : Google Scholar : PubMed/NCBI
19	Narayan VM, Konety BR and Warlick C: Novel biomarkers for prostate cancer: An evidence-based review for use in clinical practice. Int J Urol. 24:352–360. 2017. View Article : Google Scholar : PubMed/NCBI
20	Fang E, Zhang X, Wang Q and Wang D: Identification of prostate cancer hub genes and therapeutic agents using bioinformatics approach. Cancer Biomark. 20:553–561. 2017. View Article : Google Scholar : PubMed/NCBI
21	Nandi D, Cheema PS, Jaiswal N and Nag A: FoxM1: Repurposing an oncogene as a biomarker. Semin Cancer Biol. 52:74–84. 2018. View Article : Google Scholar : PubMed/NCBI
22	Liao SG, Cheng HH and Lei Y: C-reactive protein is a prognostic marker for patients with castration-resistant prostate cancer. Oncol Res Treat. 39:266–271. 2016. View Article : Google Scholar : PubMed/NCBI
23	Ma X, Du T, Zhu D, Chen X, Lai Y, Wu W, Wang Q, Lin C, Li Z, Liu L and Huang H: High levels of glioma tumor suppressor candidate region gene 1 predicts a poor prognosis for prostate cancer. Oncol Lett. 16:6749–6755. 2018.PubMed/NCBI
24	Mu J, Fan L, Liu D and Zhu D: Overexpression of shugoshin1 predicts a poor prognosis for prostate cancer and promotes metastasis by affecting epithelial-mesenchymal transition. OncoTargets Ther. 12:1111–1118. 2019. View Article : Google Scholar
25	Cui F, Hu J, Ning S, Tan J and Tang H: Overexpression of MCM10 promotes cell proliferation and predicts poor prognosis in prostate cancer. Prostate. 78:1299–1310. 2018. View Article : Google Scholar : PubMed/NCBI
26	Li T, Wang Q, Hong X, Li H, Yang K, Li J and Lei B: RRBP1 is highly expressed in prostate cancer and correlates with prognosis. Cancer Manag Res. 11:3021–3027. 2019. View Article : Google Scholar : PubMed/NCBI
27	Salem DA, Scott D, McCoy CS, Liewehr DJ, Venzon DJ, Arons E, Kreitman RJ, Stetler-Stevenson M and Yuan CM: Differential expression of CD43, CD81, and CD200 in classic versus variant hairy cell leukemia. Cytometry B Clin Cytom. 96:275–282. 2019. View Article : Google Scholar : PubMed/NCBI
28	Yoo TH, Ryu BK, Lee MG and Chi SG: CD81 is a candidate tumor suppressor gene in human gastric cancer. Cell Oncol (Dordr). 36:141–153. 2013. View Article : Google Scholar : PubMed/NCBI
29	Chen F, Hu Y, Wang X, Fu S, Liu Z and Zhang J: Expression of CD81 and CD117 in plasma cell myeloma and the relationship to prognosis. Cancer Med. 7:5920–5927. 2018. View Article : Google Scholar : PubMed/NCBI
30	Jiang X, Zhang J and Huang Y: Tetraspanins in cell migration. Cell Adh Migr. 9:406–415. 2015. View Article : Google Scholar : PubMed/NCBI
31	Malla RR, Pandrangi S, Kumari S, Gavara MM and Badana AK: Exosomal tetraspanins as regulators of cancer progression and metastasis and novel diagnostic markers. Asia Pac J Clin Oncol. 14:383–391. 2018. View Article : Google Scholar : PubMed/NCBI
32	Vences-Catalan F, Rajapaksa R, Srivastava MK, Marabelle A, Kuo CC, Levy R and Levy S: Tetraspanin CD81 promotes tumor growth and metastasis by modulating the functions of T regulatory and myeloid-derived suppressor cells. Cancer Res. 75:4517–4526. 2015. View Article : Google Scholar : PubMed/NCBI
33	Hong IK, Byun HJ, Lee J, Jin YJ, Wang SJ, Jeoung DI, Kim YM and Lee H: The tetraspanin CD81 protein increases melanoma cell motility by up-regulating metalloproteinase MT1-MMP expression through the pro-oncogenic Akt-dependent Sp1 activation signaling pathways. J Biol Chem. 289:15691–15704. 2014. View Article : Google Scholar : PubMed/NCBI
34	Luo RF, Zhao S, Tibshirani R, Myklebust JH, Sanyal M, Fernandez R, Gratzinger D, Marinelli RJ, Lu ZS, Wong A, et al: CD81 protein is expressed at high levels in normal germinal center B cells and in subtypes of human lymphomas. Hum Pathol. 41:271–280. 2010. View Article : Google Scholar : PubMed/NCBI